{"database": "openregs", "table": "documents", "rows": [["FDA-2024-D-4540-0002", "FDA", "FDA-2024-D-4540", "Recommended Follow-Up Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Human Clinical Trials With Healthy Subjects; Guidance for Industry and Review Staff - Draft Guidance", "Other", "Guidance", "2024-11-27T05:00:00Z", 2024, 11, "2024-11-27T05:00:00Z", "2025-02-26T04:59:59Z", "2025-02-28T02:00:38Z", null, 1, 0, "090000648683b09f"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2024-D-4540-0002"], "units": {}, "query_ms": 58.366360841318965, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}